Elliot Marseille, founding director of UC Berkeley’s Collaborative for the Economics of Psychedelics, discusses the economics behind emerging psychedelic therapies. Topics include the societal cost of not making psychedelic therapy accessible, his work with the SABA Foundation studying HIV/AIDS treatments, issues with recent ICER report on MDMA-assisted psychotherapy, and the need for long-term studies tracking healthcare utilization post-therapy.